PROGRAM OVERVIEW

Join us at the JW Marriott in Las Vegas for the National Lipid Association's 2018 Scientific Sessions taking place April 26-29, 2018.

This premier event is packed with innovative and groundbreaking education renowned faculty, world-class research presentations in our E-Poster Hall, opportunities to build lasting professional relationships and more!

Key topics include:

  • Global updates regarding Familial Hypercholesterolemia syndrome, perspectives from South America, Europe, and North America
  • Updates on PSCK9 Inhibition - Trials and Data Outcome plus the relevance to clinical practice
  • Approaches and considerations for Lp(a) measurement in clinical practice, including strategies for the management of patients with elevated Lp(a)

Don't miss the NLA's marquee event. See you in Las Vegas!

 

 

 

 

You may need to disable administrative overlay in your Drupal record

Edit Parent - PROGRAM (visibility Show)

AGENDA

Thursday, April 26, 2018
2:30PM-3:30PM CME/CE Symposium: The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke
4:00-6:00PM NLA Special Opening Session: Expert Debate on CVD Risk Reduction in the Cardiometabolic Patient
4:00-4:05PM PLA President’s Welcome- Yehuda Handelsman, MD, FNLA  
4:05-4:15PM Introduction and Pre-Test  
4:15-4:20pm Patient Case Overview Paul D. Rosenblit, MD, PhD
4:20-4:25PM Evolving Approach To Prevention Christie M. Ballantyne, MD
4:25-4:35PM Debate Presentation #1 – Ezetimibe Joseph J. Saseen, PharmD
4:35-4:45PM Debate Presentation #2 – PCSK9 inhibitors Robert P. Giugliano, MD
4:45-4:55PM Debate Presentation #3 - SGLT2 inhibitors & GLP-1 Agonists Valentina Rodriguez, MD
4:55-5:05PM Debate Presentation #4 - DAPT/Anticoagulation Pam R. Taub, MD
5:05-5:15PM Debate Presentation #5 - Anti-inflammatory agents Peter H. Jones, MD
5:15-5:20PM Debate Commentary Christie M. Ballantyne, MD
Paul D. Rosenblit, MD, PhD
5:20-5:25PM Audience Voting  
5:25-5:30PM Post-Test  
5:30-5:40PM Expert Panel Discussion  
5:40-6:00PM Audience Q&A  
6:00PM-7:00PM Welcome Reception in Exhibit Hall
7:00PM-9:00PM CME/CE Dinner Symposium: Cardiovascular Outcomes Trials and Expert Consensus Decision Pathways: Interpreting the Evidence with Non-Statin Therapies
Friday, April 27, 2018
6:00AM-8:00AM CME/CE Breakfast Symposium: Test Your Confidence in the Use of PCSK9 Inhibitors – The Game On! Challenge
7:00AM-8:00AM Breakfast in Exhibit Hall
7:50AM-8:00AM SELA Business Meeting
8:00AM-9:25AM Session I - Familial Hypercholesterolemia in Children- Moderator: Don P. Wilson, MD, FNLA
8:00AM-8:05AM ARS Questions
8:05AM-8:25AM Child-Parent Screening for Familial Hypercholesterolemia: Earlier Detection and Prevention David Wald, MBBS, MD
8:25AM-8:45AM When is the Right Time to Treat Children with FH? Julie St Pierre, MD, PhD
8:45AM-9:05AM Managing Pediatric Patients as an Adult Lipidologist Ann Liebeskind, MD
9:05AM-9:25AM Q&A Panel & ARS
9:25AM-9:30AM Intermission
9:30AM-9:50AM NLA President's Address
9:50AM-10:25AM W. Virgil Brown Distinguished Achievement Award & Lectureship
9:50AM-9:55AM W. Virgil Brown Distinguished Achievement Award Presentation
9:55AM-10:15AM W. Virgil Brown Distinguished Achievement Award Lecture Penny Kris-Etherton, PhD, RDN, CLS, FNLA
10:15AM-10:25AM Question and Answer  
10:25AM-10:55AM Break in Exhibit Hall
10:55AM-12:20PM Session II - Clinical Updates on PCSK9 Inhibition- Moderators: Michael Shapiro, DO, FNLA & Nathan Wong, PhD, FNLA
10:55AM-11:00AM ARS Questions
11:00AM-11:20AM Update on ODYSSEY Outcomes Vera A. Bittner, MD, MSPH, FNLA*
11:20AM-11:40AM Further Insights on the FOURIER Data Robert P. Giugliano, MD, SM
11:40AM-12:00PM Clinical Relevance - An Update on Clinical Trials - How Will This Affect Practice in the Future? Pamela B. Morris, MD, FNLA*
12:00PM-12:20PM Q&A Panel & ARS
12:20PM-12:30PM NELA Business Meeting
12:30PM-1:30PM Lunch in Exhibit Hall
12:30PM-1:30PM Non-CME Lunch Expert Theaters
1:30PM-2:55PM Session III - Unique Underserved Issues and Gender- Moderators: Eric Gupta, PharmD, FNLA & Jessica Durham, ARNP, FNLA
1:30PM-1:35PM ARS Questions
1:35PM-1:55PM Managing Lipid and CVD Risk Factors Associated with Transgender Medicine Vin Tangpricha, MD, PhD
1:55PM-2:15PM Menopause and CVD Risk: Changes in Lipids at Midlife—What’s the Link? Samar R. El Khoudary, PhD, MPH
2:15PM-2:35PM Premature Ovarian Insufficiency: Challenges in Management of CVD Risk Melissa F. Wellons, MD
2:35PM-2:55PM Q&A Panel & ARS
2:55PM-3:05PM Break
3:05PM-4:30PM Session IV - Triglycerides and HDL Interactions- Moderators: Robert Greenfield, MD, FNLA & Ira Goldberg, MD, PhD
3:05PM-3:10PM ARS Questions
3:10PM-3:30PM LDL and HDL species and size: Which are bad, which are good? Frank M. Sacks, MD, FNLA*
3:30PM-3:50PM Sorting Through the Evidence with HDL Marina Cuchel, MD, PhD
3:50PM-4:10PM Triglyceride and CVD: Time to Treat? Ira J. Goldberg, MD, FNLA*
4:10PM-4:30PM Q&A Panel & ARS
4:30PM-5:20PM Session V - State of the Art Developments in Lipid Science- Moderator: Sergio Fazio, MD, PhD, FNLA
4:30PM-4:35PM ARS Questions
4:35PM-4:50PM CRISPR - Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia Kiran Musunuru, MD, PhD, MPH
4:50PM-5:05PM Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Disease Elena Aikawa, MD, PhD
5:05PM-5:20PM Q&A Panel and ARS
5:30PM-6:30PM PLA Chapter Networking Social (PLA Members Only)
6:30PM-8:30PM CME/CE Dinner Symposium: Clinicians Live: Management Implications of Non-HDL Lipids and Inflammation in CAD
8:30PM-9:00PM Women in Lipidology Section Event
Saturday, April 28, 2018
6:00AM-8:00AM CME/CE Breakfast Symposium: The Emerging Role of Eicosapentaenoic Acid (EPA), Docosahexanoic Acid (DHA) in Atherosclerosis
7:00AM-8:00AM Breakfast in Exhibit Hall
7:50AM-8:00AM SWLA and MWLA Business Meeting
8:00AM-9:20AM Session VI - What’s New in Hypertension: 2018- Moderators: Michael Bloch, MD, FNLA & Nathan Wong, PhD, FNLA
Endorsed by American Heart Association | American Stroke Association, Western States Affiliate
8:00AM-8:05AM ARS Questions
8:05AM-8:25AM Update on Hypertension: What the New Guidelines Really Say Sandra J. Taler, MD
8:25AM-8:45AM Resistant Hypertension: A Practical Approach to the Updated Guideline Michael Bloch, MD, FNLA*
8:45AM-9:05AM Treating Hypertension in the High-Risk Cardio-Metabolic Patient: A Focus on Outcomes George L. Bakris, MD
9:05AM-9:20AM Q&A Panel & ARS
9:20AM-9:30AM PLA Business Meeting
9:30AM-10:00AM Break in Exhibit Hall
10:00AM-11:25AM Session VII - Lipoprotein(a) as a Risk Factor and Treatment Target for CVD- Moderators: Marlys Koschinsky, PhD & Sergio Fazio, MD, PhD, FNLA
10:00AM-10:05AM ARS Questions
10:05AM-10:25AM Lp(a) Function and Metabolism: Identification and Closing of Knowledge Gaps Marlys L. Koschinsky, PhD
10:25AM-10:45AM Challenges in Lp(a) Measurement Santica Marcovina, PhD, DSc
10:45AM-11:05AM Present and Future Therapy for Lp(a) Patrick M. Moriarty, MD, FNLA
11:05AM-11:25AM Q&A Panel & ARS
11:25AM-11:55AM NLA and Foundation of the NLA Business Meeting and Poster Winners Announced
11:55AM-12:55PM Lunch in Exhibit Hall
11:55AM-12:55PM Non-CME Lunch Expert Theaters
12:55PM-1:55PM Oral Presentations- Moderator: P. Bart Duell, MD, FNLA
1:55PM-3:20PM Session VIII - Update on Familial Hypercholesterolemia from a Global Perspective- Moderators: P. Bart Duell, MD, FNLA & Raul Santos, MD
1:55PM-2:00PM ARS Questions
2:00PM-2:20PM South America Perspectives on Familial Hypercholesterolemia Alberto J. Lorenzatti, MD
2:20PM-2:40PM Familial Hypercholesterolemia: The European Experience Anthony S. Wierzbicki, DM, DPhil, FRCPath
2:40PM-3:00PM Update from North America on Familial Hypercholesterolemia Christie M. Ballantyne, MD, FNLA
3:00PM-3:20PM Q&A Panel & ARS
3:20PM-4:20PM Session IX - Lipids Are My Lifestyle- Moderator: Geeta Sikand, RD, FNLA
3:20PM-3:25PM ARS Questions
3:25PM-3:45PM Nutrition and CV Mortality: Taking the DIE out of Your DIET Kim A. Williams, Sr., MD
3:45PM-4:05PM Dietary Fats and Cardiovascular Disease: Brief Review of the Current Scientific Evidence and Tips for Practical Application Carol F. Kirkpatrick, PhD, MPH, RDN, CLS, FNLA
4:05PM-4:20PM Q&A Panel & ARS
4:20PM-4:25PM Break
4:25PM-4:55PM Late Breakers
5:00PM-5:30PM VIP Mixer for Fellows of the NLA
5:30PM-7:00PM Honors and Awards Ceremony
7:30PM-10:30PM NLA Foundation Event
Sunday, April 29, 2018
7:00AM-8:00AM Breakfast
8:00AM-9:25AM Session X - Putting Research into Practice- Moderator: James Underberg, MD, FNLA
8:00AM-8:05AM ARS Questions
8:05AM-8:25AM Physical activity, sedentary time, TV viewing, physical fitness and cardiovascular disease risk in adolescents: The HELENA study Lauren Williams, MCN, RD, LD
8:25AM-8:45AM Dear Vitamin D, Lack of You May Be the Reason For my Pain? Roda Plakogiannis, PharmD, CLS, FNLA
8:45AM-9:05AM Management of Statin Intolerance in 2018: Still More Questions Than Answers (but we’re getting better) Margo B. Minissian, PhD, ACNP, CLS
9:05AM-9:25AM Q&A Panel & ARS
9:25AM-10:50AM Session XI - The High CV Risk Patient: It’s Not Just about Lipids- Moderators: Eric Gupta, PharmD, FNLA & Robert Greenfield, MD, FNLA
9:25AM-9:30AM ARS Questions
9:30AM-9:50AM If You Don't Snooze, You Lose: Obstructive Sleep Apnea and CVD Edward Chafizadeh, MD
9:50AM-10:10AM When CV Health Goes Up in Smoke: CV Risks of e-Cigarettes and Marijuana Tina M. Kaufman, PhD, PA-C
10:10AM-10:30AM Obesity and CVD Jeopardy: When Bariatric Surgery is the Answer Catherine J. McNeal, MD, PhD, FNLA
10:30AM-10:50AM Q&A Panel & ARS
10:50AM Adjourn

FEATURED PRESENTATIONS

Lp(a) Function and Metabolism: Identification and Closing of Knowledge Gaps
Saturday, April 28 - 10:00-11:25AM

Lipoprotein(a) (Lp(a)) is a unique lipoprotein class that is an independent, and likely causal, risk factor for coronary heart disease and other atherothrombotic disorders as well as calcific aortic valve disease. Lp(a) concentrations are largely genetically determined with levels greater than 50 mg/dL (~125 nmol/L) present in at least 20% of the global population. Lp(a) continues to challenge both researchers who are grappling with understanding its mechanism of action as well as clinicians who wish to include Lp(a) as a component of risk assessment. In this session, we will provide up-to-date information on the evidence base for Lp(a) as a risk factor for cardiovascular disease in both primary and secondary prevention settings. We will also discuss the most current thinking on approaches and considerations for Lp(a) measurement in the clinic. Current strategies for managing patients with elevated Lp(a) levels will be considered, along with a look at promising future therapeutic approaches for Lp(a) lowering. 

 

 

 

 


Marlys L. Koschinsky, PhD

Scientific & Executive Director
Robarts Research Institute
Schulich School of Medicine & Dentistry
Western University
London, ON, Canada

Dietary Fats and Cardiovascular Disease: Brief Review of the Current Scientific Evidence and Tips for Practical Application
Saturday, April 28 - 3:45-4:05PM

Dietary fats and their impact on cardiovascular disease (CVD) seems to be a never-ending controversy. Health professionals are frequently asked questions by their patients about headlines they see in the media that conflict with the evidence-based dietary guidelines regarding dietary fat intake. Dr. Kirkpatrick will review the current scientific evidence regarding the relationship between dietary fats and CVD and provide practical application tips for health professionals to use as they educate their patients on achieving a balance for dietary fats intake that is supported by the evidence and tips for cardioprotective eating habits, in general.

 

 

 

 


Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

Program Planner
Wellness Center Director
Clinical Assistant Professor
Idaho State University
Pocatello, ID

Putting Research into Practice
Sunday, April 29 - 8:00-9:25AM

There is a constant flow of journal publications being sent out in the world of each day, and every day practitioners must decide if the information they contain is relevant to their clinical practice. Will the information in this article impact the care experts provide every day? Join Lauren Williams, MCN, RD, Roda Plakogiannis, PharmD, Margo Minissian, PhD, ACNP, and moderator James A. Underberg, MD, MS, FNLA as they examine recent journal publications and how the information contained in them has impacted the care being provided.

 

 

 

 


Lauren Williams, MCN, RD, LD

Clinical Dietitian II
Division of Pediatric Endocrinology
Cook Children's Medical Center
Fort Worth, TX


Roda Plakogiannis, PharmD, CLS, FNLA

Associate Professor of Pharmacy Practice
Long Island University, New York
New York, NY
 


Margo B. Minissian, PhD, ACNP, CLS

Nurse Scientist
Cardiology Nurse Practitioner
Cedars-Sinai Heart Institute
Barbra Streisand Women's Heart Center
Los Angeles, CA

ACCREDITATION

2018 Annual Scientific Sessions Accreditation: 
 
Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.
 
Type of Activity
Live Activity
Application
 
Educational Objectives
At the conclusion of this activity, all participants should be able to:
• Discuss strategies to improve the knowledge, skills or performance of the healthcare team;
 
NLA Special Opening Session: Expert Debate on CVD Risk Reduction in the Cardiometabolic Patient 
 
• Summarize the evidence-based recommendations for therapeutic interventions to reduce the risk for cardiovascular complications among patients with comorbidities, including type 2 diabetes and hypertriglyceridemia. 
• Demonstrate the potential use of non-traditional therapies in an overall cardiovascular disease risk reduction management plan. 
• Analyze the current evidence base that is cross-pollinating specialties and transforming cardiovascular risk management. 
 
Session I- Familial Hypercholesterolemia in Children 
 
• Apply screening technologies in clinical practice to identify Familial Hypercholesterolemia (FH). 
• Appraise the evidence for screening, diagnosing, and treating FH in children. 
 
W. Virgil Brown Lecture Award
 
• Discuss the evolution of the treatment of dyslipidemia through diet and nutritional therapies. 
 
Session II- Clinical Updates on PCSK9 Inhibition 
 
• Assess the implications of lipid treatment outcomes trials for the future clinical management of patients with dyslipidemia. 
• Apply important recent clinical trials research to daily clinical practice.
 
Session III- Unique Underserved Issues and Gender 
 
• Recognize population differences that may impact clinical care and implement interventions to reduce cardiovascular risk in the transgender population.
• Explain the cardiovascular risks associated with menopause.
• Discuss the risks associated with premature ovarian insufficiency and the impact on Cardiovascular Disease (CVD) risk.
 
Session IV- Triglycerides and HDL Interactions 
 
• Describe methods and implications of determining High Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) characteristics such as particle size, pattern, and number. 
• List the available and potential laboratory and clinical measures of HDL functionality.
• Assess the status of current and emerging treatment options for triglyceride management in CVD prevention. 
 
Session V- State of the Art Developments in Lipid Science 
 
• Assess the potential of new and emerging therapeutic approaches to manage dyslipidemia. 
 
Session VI- What’s New in Hypertension: 2018
 
• Evaluate the clinical implications of the 2017 Hypertension guidelines.
• Outline the management of resistant hypertension within the current guidelines. 
• Discuss the controversies and impact of the new hypertension guidelines on clinical management in high risk patients.
 
Session VII- Lipoprotein(a) as a Risk Factor and Treatment Target for CVD 
 
• Discuss the potential role of Lipoprotein(a) (Lp(a)) in risk assessment and the management of CVD.
• Describe the different measurements of Lp(a) and the potential clinical implications.
• Explore the therapies that reduce Lp(a) and the future novel approaches. 
 
Oral Poster Presentations
 
• Critically appraise emerging research and its applications to daily clinical practice.
 
Session VIII- Update on Familial Hypercholesterolemia from a Global Perspective
 
• Evaluate the clinical effects, efficacy and outcomes data for treatment options for FH patients.
 
Session IX- Lipids Are My Lifestyle
 
• Identify the impact of specific diets on the prevention of CVD.
• Assess the effect of dietary fat on lipid levels and their impact on the development of CVD.
 
Session X- Putting Research into Practice
 
• Demonstrate the practical application of the current publications to the clinical evaluation and management of patients with dyslipidemia.
 
Session XI- The High CV Risk Patient: It’s Not Just about Lipids
 
• Apply appropriate evaluation and management of sleep apnea to patients with comorbid CVD. 
• Describe the impact of e-cigarettes and marijuana smoking on risk assessment and management of CVD.
• Implement practical treatment protocols for the management of obesity in the high CVD risk patient. 
 
 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.75 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
 
 
  In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Physician Credit Designation Statement 
The National Lipid Association designates this live activity for a maximum of 18.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity. 
 
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
 
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 19 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
 
Pharmacist Accreditation Statement
 Universal Activity Number J0007192-0000-18-005-L01-P (Application)
This Activity has been approved for 18.75 contact hour(s) (1.875 CEUs) of the Accreditation Council for Pharmacy Education
 
Nursing
The maximum number of hours awarded for this CE activity is 17.7 contact hours.

For the advanced practice nurse, this activity has 4.0 contact hours of pharmacotherapy content.

 
Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
 
Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. 
 
Commercial Support:
Full notification of commercial support will be provided in the activity syllabus.

ANCILLARY COURSES

Are you new to Lipidology or just looking to brush up on the changing information coming out in the field? Attend one of our ancillary courses taught by Experts in the area of Lipidology:

See expert analysis of unique cases unveiled at the inaugural Donald S. Fredrickson Conference on Familial Lipoprotein Disorders April 29 in Las Vegas, in conjunction with Scientific Sessions. 

The NLA's Masters in Lipidology course provides an advanced examination of the core curriculum in Clinical Lipidology. This course is designed for any health care professional with experience in Lipidology who desires advanced training. Experts in the field of Lipidology will lecture on advanced concepts and guide participants through interactive learning scenarios that provide tools and skills to further advance personal standards of practice. It is recommended that attendees have already completed preparatory coursework (eg Foundations of Lipidology [formerly Lipid Academy] or similar core curriculum training).

The NLA's Foundations of Lipidology course, formerly Lipid Academy, provides an introductory review of the core curriculum in Clinical Lipidology. This course is designed for any healthcare professional seeking to learn the fundamentals of Lipidology. Experts in Lipidology will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in a lipid practice, and prepare for advanced training.

Delete PROGRAM

Edit Parent - SPECIAL EVENTS (visibility Show)

FOUNDATION EVENT

 

The Foundation of the National Lipid Association’s Dinner Gala and Silent Auction featuring Dr. Alan Brown and his band, This End Up

Going once… going twice… sold! Claim your ticket to the Foundation of the National Lipid Association’s Dinner Gala and Silent Auction before they sell out.

At this year’s event, we will hold a top-notch silent auction with a variety of unique items ranging from event tickets, getaways and more! The evening will also feature dinner, dancing and special recognition for the winner of the Foundation’s Clinician/Educator Award. In addition to having a memorable night, you will also be supporting the important initiatives of the Foundation! Back by popular demand, incoming NLA President Alan Brown and his band, This End Up, will entertain the crowd with music for the night.

The ticket price includes dinner and open bar. 

We are collecting items for the 2018 Silent Auction.  If you are interested in making a donation to be included, please contact Chealsea Schroeder at cschroeder@lipidfoundation.org. Donated items can come from a variety of categories including but not limited to trips and getaways, sports and sporting events, gift certificates, electronics, food and drink, and much more. 

SYMPOSIA

 

CME/CE Symposium

The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke

Thursday, April 26
Registration and Refreshments: 2:15 - 2:30pm
Symposium: 2:30 - 3:30pm
Marquis Ballroom 4-8

This live symposium held in conjunction with the National Lipid Association 2018 Scientific Sessions will outline the role of PCSK9 inhibitor therapeutics in preventing heart attack and stroke in a new era of preventive cardiology. The expert faculty will review risk stratification for patients with cardiovascular disease (CVD). Cardiovascular outcomes data from ODYSSEY and FOURIER PCSK9 inhibitor clinical trials will be analyzed, utilizing an interactive panel format to translate evidence-based medicine to clinical decision making. The faculty will evaluate best practices for optimally managing preventive cardiology with PCSK9 inhibitor therapeutics.

FACULTY

James A. Underberg, MD, MS, FNLA
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY

Alan S. Brown, MD, FNLA
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL

Peter H. Jones, MD, FNLA
Director, Division of Cardiology
Associate Professor of Medicine Co-director,
Lipid Metabolism and Atherosclerosis Clinic Center for
Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX

Robert P. Giugliano, MD, SM
Executive Committee, FOURIER Trial
Senior Investigator, TIMI Study Group
Physician, Cardiovascular Medicine
Brigham and Women's Hospital
Associate Professor
Harvard Medical School
Boston, MA

Daniel E. Soffer, MD, FNLA
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA

Refreshments provided by the NLA
Hosted by AcademicCME
This activity is supported by educational funding provided by Sanofi US and Regeneron Pharmaceuticals

CME/CE Dinner Symposium

Cardiovascular Outcomes Trials and Expert Consensus Decision Pathways: Interpreting the Evidence with Non-Statin Therapies

Thursday, April 26
7:00 – 9:00pm
Marquis Ballroom 1-3

The knowledge base on the use of non-statin therapies for LDL-C lowering has rapidly increased with the release of primary results and secondary analyses from cardiovascular outcome trials (CVOTs). The ongoing presentation and publication of evidence from the IMPROVE-IT and FOURIER trials has created a need for lipidologists to be informed of this information which may have a significant impact on their clinical practice. Furthermore, an assessment of the ODYSSEY OUTCOMES trial, presented at ACC 2018, and a comparison/contrast of the FOURIER and ODYSSEY OUTCOMES trials are needed to assist lipidologists with clinical decision-making regarding prudent use of PCSK9 inhibitors. As a result, best practice is rapidly evolving with non-statin therapies, necessitating the release of updated recommendations from the NLA on the use of PCSK9 inhibitors, new dyslipidemia guidelines from the AACE/ACE, and a focused update of the ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk. In this symposium, chair Dr. Robert Giugliano, and faculty members Dr. Christie Ballantyne, Dr. Eliot Brinton, Dr. Joseph Saseen, and Dr. Peter Toth will provide updates to landmark CVOTs, engage in a lively and insightful panel discussion of the FOURIER and ODYSSEY OUTCOMES trials, describe the impact of emerging data on clinical practice, provide recommendations for the use of non-statin therapies, and identify key issues in the development of new guidelines.

CHAIR

Robert Giugliano, MD, SM
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

FACULTY

Christie Ballantyne, MD
Professor of Medicine
Chief, Section of Cardiology
Baylor College of Medicine
Houston, Texas

Eliot Brinton, MD
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, Utah

Joseph Saseen, PharmD
Professor and Vice Chair
Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado
Anschutz Medical Campus
Aurora, Colorado

Peter Toth, MD, PhD
Professor
Clinical Family
and Community Medicine
University of Illinois School of Medicine
Peoria, Illinois

Dinner provided by the NLA
Hosted by Vox Media
This activity is supported by educational funding provided by Amgen Inc.

CME/CE Breakfast Symposium

Test Your Confidence in the Use of PCSK9 Inhibitors – The Game On! Challenge

Friday, April 27
6:00 – 8:00am

Marquis Ballroom 1-3

As clinical data emerge regarding the benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, obtaining access to these agents remains a barrier to their use. Given the high prevalence of patients on statin therapy who fail to meet LDL-C target goals, continuing education is crucial regarding the latest clinical advances and recommendations for the use of PCSK9 inhibitors, as well as practical strategies to gain access to these agents to improve patient outcomes. This educational activity will feature a panel of experts who will review the latest recommendations regarding the use of PCSK9 inhibitors and the impact of their use on cardiovascular outcomes. They will also assess the latest data regarding the benefits and safety of achieving low LDL-C goals, as well as detail practical strategies to improve access to treatment. Clinical cases will be presented to highlight the key educational objectives. In addition, participants will engage in Game On! - an interactive, confidence-based activity.

FACULTY

James A. Underberg, MD, MS, FNLA
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY

Pamela B. Morris, MD, FNLA
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina

Michael H. Davidson, MD, FNLA
Director of the Lipid Clinic
The University of Chicago, Pritzker School of Medicine
Chicago, IL

Breakfast provided by the NLA
Hosted by Vindico Medical Education

This activity is supported by educational grant from Amgen.

CME/CE Dinner Symposium

Clinicians Live: Management Implications of Non-HDL Lipids and Inflammation in CAD

Friday, April 27
6:30 – 8:30pm

Marquis Ballroom 1-3

This 2-hour, highly interactive CME-certified symposium will feature a faculty of 5 leading international experts who will address the complex interrelationship of non-HDL-C (including HTG) and inflammatory biomarkers associated with cardiovascular disease and its outcomes. The intersection of lipids, inflammatory pathways, and vascular pathways in atherosclerosis will be examined. This educational activity will provide the opportunity for the multidisciplinary faculty and symposium participants to work through complex issues that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol and triglycerides, many (or most) of whom have been sub-optimally managed.

 

CHAIR

Sergio Fazio, MD, PhD
William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine, Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR

FACULTY

Deepak L. Bhatt, MD, MPH
Executive Director
Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor
Harvard Medical School
Boston, MA

Aruna Pradhan, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Physician
Division of Preventive Medicine
Brigham and Women's Hospital
Staff Cardiologist
VA Boston Healthcare System
Boston, MA

Suzanne Shugg, APN, DNP
Director of Preventive Cardiovascular Care
New Jersey Cardiology Associates
CEO, Teleplus Healthcare
Assistant Professor
Rutgers School of Nursing
Newark, NJ

James A. Underberg, MD, MS
Clinical Lipidology
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, NY

 
 

Dinner provided by the NLA
Hosted by Medtelligence
This activity is supported by educational funding provided by Amarin Pharma Inc.

CME/CE Breakfast Symposium

The Emerging Role of Eicosapentaenoic Acid(EPA) and Docosahexanoic Acid(DHA) in Atherosclerosis

Saturday, April 28
6:00 – 8:00am

Marquis Ballroom 1-3

Join us for this exciting, dynamic, and clinically-focused symposium highlighting the most relevant data from experts in the field on DHA, EPA, and their varying effects on atherosclerosis and relevance to cardiovascular risk. During this 2-hour journey Dr. Mason will show the effects of EPA on HDL cholesterol efflux and the differential effects of EPA and DHA on lipoprotein oxidation. Dr. Nelson will take you through the intriguing diverse array of imaging studies involving EPA and DHA, including CIMT, CTA, IVUS, Coronary Angiography, and OCT. Dr. Budoff will close the session by covering data from the EVAPORATE and AQUAMARINE trials and predicting what lies ahead for the future of DHA and EPA in imaging.

MODERATOR

Karen E. Aspry, MD, MS, FACC, FNLA
Director, Lipid Clinic and Cardiovascular Disease Prevention Program
Lifespan Cardiovascular Institute
East Greenwich, RI
Diplomate, American Board of Clinical Lipidology

SPEAKERS

Matthew J. Budoff, MD
Professor of Medicine, UCLA
Endowed Chair of Preventive Cardiology
Los Angeles Biomedical Research Institute

John R. Nelson MD, FACC, FNLA, FASNC
Director, California Cardiovascular Institute
Past President-Pacific Lipid Association
ACC-CA Governmental Relations Committee-Member

R. Preston Mason, PhD
Director, Lipid Biophysics Laboratory
Cardiovascular Division
Brigham & Women’s Hospital
Harvard Medical School

EXPERT THEATRES

Friday, April 27 | 12:30 - 1:30pm

Repatha® (evolocumab): Putting it into Practice

Location: Cataluna

Faculty: Peter P. Toth, MD, PhD, FCCP, FAHA, FESC, FACC

Hosted by Amgen

Cardiovascular Disease Burden in the US and Clinical Evaluation of VASCEPA® (icosapent ethyl)

Location: Valencia

Faculty:
Eliot Brinton, MD
President, Utah Lipid Center
Salt Lake City, UT

Hosted by Amarin Pharma Inc.

Saturday, April 28 | 11:55am - 12:55pm

Hypertriglyceridemia-Induced Pancreatitis:  How Lipidologists Can Partner To Optimize Complex Care

Location: Valencia
Panelists:
Vikesh Singh, MD, MSc
Director, Pancreatitis Center
Associate Professor of Medicine
Johns Hopkins University

David J. Davidson, MD
Clinical Lipidologist
NorthShore Medical Group
Bannockburn, IL

Moderator:
James A. Trippi, MD
Interventional Cardiology
St. Vincent Medical Group
Indianapolis, IN

Hosted by Akcea Therapeutics

Criticality of LDL-C Lowering

Location: Cataluna

Faculty:
Harold Edward Bays, MD, FOMA, FTOS, FACC, FACE, FNLA
Medical Director / President
Louisville Metabolic and Atherosclerosis Research Center

Hosted by Amgen

LATE BREAKERS

Saturday, April 28, 2018 | 4:25–4:55pm
JW Marriott Las Vegas - Marquis Ballroom 4-8

The Efficacy and Safety of Inclisiran, An RNAi Therapeutic Targeting PCSK9, in Different Patient Populations
Dr. David Kallend, MBBS (Lon)
The Medicines Company


Severe Hypercholesterolemia in a 2-Year-Old Child

Susanna Horner
University of North Texas Health Science Center

SILENT AUCTION

To make an early bid, email cschroeder@lipidfoundation.org.

Sport your lipid gear with this hat designed by Dr. Jamie Underberg.

Mini helmet signed by Miami Dolphins Quarterback Ryan Tannehill.

Signed pointe shoes from a dancer at the New York City Ballet. Includes biography of dancer.

Signed small sized basketball by the Broadcast Team at TNT.
Shaquille O'Neal, Ernie (EJ) Johnson Jr., Kenny ( The Jet) Smith, and Charles Barkley

Electrify your night at the specially designed
state-of-the-art Blue Man Theater at Luxor Hotel and Casino.
Ticket voucher for 2 guests.
Valid until October 30, 2018

Timeless tri-color handmade rolling bracelet.
18kt vermeil gold over silver.

Lifetime Membership will ensure
continuous membership with the National Lipid Association and the ability to obtain the special member rate at each NLA meeting.

2 night stay with breakfast for 2 each morning.
Valid until April 28, 2019

2 bedrooms, 1.5 baths
(1 King bed, 1 Queen bed, 1 floor mattress)
Saint-Georges-de-Malbaie, Québec, Canada
1 week during September 2018

4 bedrooms, 1 ¼ baths
(2 with double beds and 2 with queen beds)
Lieutenant Island in Wellfleet, MA
September 9-16, 2018, September 23-30, 2018
or October 5-12, 2018

 

Delete SPECIAL EVENTS

Edit Parent - ENGAGE (visibility Show)

SOCIAL MEDIA

 

 

Be part of the conversation and get the latest news and announcements from the 2018 Scientific Sessions. Follow the NLA on Facebook, Twitter, LinkedIn, and Instagram. Use the hashtag #NLASessions when posting about the meeting.

Connect With Exhibitors

Accreditation Council for Clinical Lipidology (ACCL)
The ACCL offers the Clinical Lipid Specialist (CLS) certification program to licensed physicians, nurses, nurse practitioners, physician assistants, pharmacists, registered dietitian/nutritionists, clinical exercise physiologists and other healthcare professionals who meet qualifying criteria. The CLS program certifies and validates one's professional credentials to provide specialized care to patients with dyslipidemia and related cardiometabolic conditions.
www.lipidspecialist.org

Admera Health
Admera Health is a CLIA-certified CAP-accredited laboratory that utilizes Next-Generation Sequencing technology to advance personalized medicine. Our expertise includes pharmacogenomics, cardiovascular disease, and non-invasive cancer screening. Physicians and patients receive diagnostic test results in a distilled and manageable report, giving them the relevant information to make more informed treatment decisions.
www.admerahealth.com

Aegerion Pharmaceuticals
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes JUXTAPID® and MYALEPT®. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
www.novelion.com

Akcea Therapeutics
Akcea Therapeutics is a pharmaceutical development and commercialization company focused on helping patients living with serious cardiometabolic lipid disorders.  Akcea’s pipeline includes advanced RNA-targeted antisense therapeutics being investigated to treat patients with a wide range of lipid disorders including rare hyperlipidemias, hyperlipoproteinemia(a), and hypertriglyceridemia with cardiovascular risk. Volanesorsen, Akcea's most advanced investigational drug, has completed Phase 3 trials to reduce ApoC-III protein production and to lower triglycerides to treat patients with familial chylomicronemia syndrome (FCS) and is in Phase 3 trials for patients with familial partial lipodystrophy (FPL). 
www.akceatx.com

Akcea Therapeutics Medical Information
Akcea Therapeutics is a pharmaceutical development and commercialization company focused on helping patients living with serious cardiometabolic lipid disorders.  Akcea’s pipeline includes advanced RNA-targeted antisense therapeutics being investigated to treat patients with a wide range of lipid disorders including rare hyperlipidemias, hyperlipoproteinemia(a), and hypertriglyceridemia with cardiovascular risk. Volanesorsen, Akcea's most advanced investigational drug, has completed Phase 3 trials to reduce ApoC-III protein production and to lower triglycerides to treat patients with familial chylomicronemia syndrome (FCS) and is in Phase 3 trials for patients with familial partial lipodystrophy (FPL). 
www.akceatx.com

Alexion Pharmaceuticals
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases, including lysosomal acid lipase deficiency (LAL-D), through the innovation, development and commercialization of life-changing therapies.
www.alexion.com

Amarin Pharma, Inc.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription. 
www.amarincorp.com

Ambry Genetics
We believe in the power of people working together towards one goal, one purpose. And the power that lies within our walls to make a life-changing difference. We will not stop until human disease is understood.
www.ambrygen.com

American Board of Clinical Lipidology (ABCL) 
The ABCL is an independent physician-certifying organization offering the highest benchmark of professional competency in Clinical Lipidology. Enhance your professional stature and credibility in the field, and demonstrate your commitment to the highest standards of patient care. The program is open to licensed physicians in the US and Canada.
www.lipidboard.org 

Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com

Boston Heart Diagnostics
Boston Heart Diagnostics recognizes that CVD and diabetes are complex and every patient’s story is different. A patient’s treatment plan needs to be individualized if we are to make a significant impact to improve health outcomes. Boston Heart is transforming the standard of care by providing tailored patient reports, which are created by integrating a patient’s test results, health history and food likes and dislikes. This comprehensive approach offers a more complete picture of a patient’s health. Boston Heart’s patient and healthcare provider portals are used to deliver these reports in a secure, protected environment. Boston Heart’s solutions are designed to engage and educate patients on the actions they can take toward achieving and maintaining a healthier lifestyle.
www.bostonheartdiagnostics.com

Carlson Laboratories
Since 1965 Carlson Laboratories, Inc. has produced the freshest, purest, sward-winning vitamins, minerals, fish oils, and other nutritional supplements.
www.carlsonlabs.com

Color
Color is a personal health service that helps people understand their risk for common hereditary conditions and work with their doctor to create personalized prevention and treatment plans. Color offers genetic tests which analyze genes that are closely associated with some of the most common hereditary cancers and hereditary high cholesterol. Color tests are physician ordered and come with free board-certified genetic counseling for clients and healthcare providers.
www.color.com

Denka Seiken Co., Ltd
Denka Seiken offers assays directly quantifying (without any sample pretreatment) lipid subfractions, and also latex-enhanced turbidimetric immunoassays for specific protein biomarkers to be run on automated chemistry analyzers. The range of lipid subfraction assays includes small dense LDL, HDL3, Remnant Lipoproteins and Triglycerides in LDL particles. The latex-enhanced turbidimetric immunoassays are available for Lp(a), Cystatin C, hsCRP, RF, Myoglobin, IgE, Ferritin, etc.

Healio.com & Cardiology Today
As the official media partner, CARDIOLOGY TODAY is reporting LIVE from NLA 2018. Follow the daily news and expert perspective straight from the podium at Healio.com/NLA. Explore videos, Education/CME, In the Journals and more resources that are relevant to your practice. Gain FREE access at Healio.com/Register. Stop by our booth for your free issue of CARDIOLOGY TODAY.

ISA2018
www.isa2018.org

Kaneka Pharma America

Kowa Pharmaceuticals
Established in 2008, Kowa Pharmaceuticals America, Inc., is committed to developing and delivering safe, effective solutions in the field of cardiometabolic therapeutics. We do this by maintaining high ethical and professional standards--and it all starts with people. By empowering our employees to live this mission, we can create a healthier vision for the future.
www.kowapharma.com

Medicure Pharma, Inc.
Medicure Pharma is focused on the development and commercialization of a growing portfolio of cardiovascular therapeutics for the U.S. market. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients and healthcare providers.
www.medicure.com

Med Learning Group
A Virtual Reality Learning Experience where participants will have the opportunity to wear Oculus Virtual Reality headsets and be completely immersed in a 360 degree virtual world inside a blood vessel. The leaners will virtually experience what the patient is going through in terms of disease symptoms and treatment effects, which will help them learn the importance of personalized treatment, physician-patient communication, and patient-reported outcomes. This learning experience will be broken into several virtual themes including:
o The Role of LDL-C in the pathophysiology of CVD
o Mechanisms of Action of LDL-C–Lowering Agents and their CV Outcomes for patients at high risk for CVD
www.medlearninggroup.com

MotherToBaby
MotherToBaby is the nation’s leading authority and most trusted source of evidence-based information on the safety of medications and other exposures during pregnancy and while breastfeeding. MotherToBaby Pregnancy Studies is evaluating the effects of FH and ASCVD along with the medications used to treat these diseases during pregnancy.
mothertobaby.org

Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health.
www.questdiagnostics.com

Retrophin Inc.
Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
www.retrophin.com

Sanofi-Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.
www.sanofi-us

The FCS Foundation
www.livingwithfcs.org

The FH Foundation
The FH Foundation is a patient-centered nonprofit organization dedicated to research, advocacy, and education of familial hypercholesterolemia (FH). Our mission is to raise awareness and save lives by increasing the rate of early diagnosis and encouraging proactive treatment. If left untreated, FH leads to aggressive and premature heart disease in women, men and children of all racial and ethnic backgrounds.
www.theFHFoundation.org

Delete ENGAGE

Edit Parent - VENUE (visibility Show)

HOTEL INFORMATION

JW Marriott Las Vegas

221 N Rampart Blvd
Las Vegas, NV

VISIT LAS VEGAS

Spring Mountain Ranch State Park
Take in the area’s history at this scenic park with a vibrant past. The park’s historic atmosphere, natural beauty, and frequent events make it a popular destination spot for visitors and locals alike.

Red Rock Canyon
Experience Nevada’s landscape at the Red Rock Canyon. This picturesque location is just a short drive from the resort and is ideal for a hike or scenic drive. Red Rock Canyon is not only known for its breathtaking views, but for its diverse wildlife as well.

TPC Las Vegas
This premier course, which is just steps away from the resort, is known for its exquisite scenery and challenging terrain. This renown course is an excellent way to relax and unwind during your stay, both on and off the course. Aside from its premier grounds, TPC Las Vegas also offers an array of dining options. 

 

Delete VENUE

Edit Parent - SUPPORT (visibility Show)

EXHIBIT IN LAS VEGAS



It is our pleasure to invite you to join us as an exhibitor at our 2018 Scientific Sessions. NLA meetings provide you with an opportunity to reach your target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians, PhD researchers, and clinical team affiliates, from an array of disciplines including nurses, nurse practitioners, physician assistants, pharmacists, exercise physiologists, and dietitians, in a uniquely intimate educational setting. We are proud to showcase not only an agenda led by distinguished faculty who are leaders in their fields, but a lively exhibit hall to act as a home-base for our attendees. On behalf of our board of directors and the members we serve, we look forward to seeing you in Las Vegas.

Submit an Application 

Download Exhibitor Prospectus

 

HOST AN EXPERT THEATER

National Lipid Association attendees are passionate healthcare providers who expect high-quality and innovative education while attending the Scientific Sessions. Add your presentation to their list of must-see events by signing up to host an Expert Theater in Las Vegas. 

Download Expert Theater Application

HOST A SYMPOSIUM

The NLA has established that independently developed CME/CE-certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members and meeting participants.


In this regard, we are pleased to offer satellite symposia opportunities in conjunction with our 2018 Scientific Sessions. Satellite symposia curriculum should include educational topics that complement or supplement the Scientific Sessions program agenda, addressing educational gaps preventing optimal patient care. Download our guidelines to view important information regarding hosting a satellite symposium, including the proposal creation and application processes. The NLA is proud to offer non-competing slots, complimentary marketing drivers, and more to our partners. 


Please contact Amina at Aresheidat@lipid.org should you have any questions or require additional information. We hope to see you in Las Vegas. 

 

Interested in non-CME programming? Please email exhibits@lipid.org
 

Download Symposia Guidelines

Delete SUPPORT


SCIENTIFIC MEETINGS CO-CHAIRS

Anne C. Goldberg, MD, FACP, FNLA

Committee Co-Chair
President, Foundation of the NLA

Professor of Medicine
Washington University School of Medicine
St. Louis, MO

James A. Underberg, MD, MS, FNLA

Committee Co-Chair
President, National Lipid Association

Clinical Assistant Professor of Medicine
Director, Bellevue Hospital Lipid Clinic
New York, NY



PROGRAM PLANNERS

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

Program Planner
Wellness Center Director
Clinical Assistant Professor
Idaho State University
Pocatello, ID

 

Pamela B. Morris, MD, FNLA

Program Planner
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Mt. Pleasant, SC

Joseph J. Saseen, PharmD, CLS, FNLA

Program Planner
Professor and Vice Chair
Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado
Anschutz Medical Campus
Aurora, CO

Alan S. Brown, MD, FNLA

Program Planner
Director, Division of Cardiology

Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL

P. Barton Duell, MD, FNLA

Program Planner
Professor of Medicine
Knight Cardiovascular Institute
School of Medicine
Oregon Health and Science University
Portland, OR

Sergio Fazio, MD, PhD, FNLA

Program Planner
William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine
Director of Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR

Ira J. Goldberg, MD, FNLA

Program Planner
Clarissa and Edgar Bronfman, Jr. Professor
Director, Division of Endocrinology, Diabetes and Metabolism
NYU Langone Medical Center
New York, NY

Yehuda Handelsman, MD, FNLA

Program Planner
President, Pacific Chapter of the NLA
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana CA

Elizabeth Jackson, MSN, ACNS-BC, CLS, FNLA

Program Planner
Cardio Texas
St. David's Medical Center
Austin, TX

Peter H. Jones, MD, FNLA

Program Planner
Director, Division of Cardiology
Associate Professor of Medicine Co-director, 
Lipid Metabolism and Atherosclerosis Clinic Center for
Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center 
Baylor College of Medicine 
Houston, TX



FACULTY

Elena Aikawa, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Director, Vascular Biology Program
Director, Heart Valve Translational Research Program
Brigham and Women’s Hospital
Boston, MA

George L. Bakris, MD

Professor of Medicine
University of Chicago Medicine
Chicago, IL

Christie M. Ballantyne, MD, FNLA

Professor of Medicine
Chief, Section of Cardiovascular Research
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Houston, TX

Vera A. Bittner, MD, MSPH, FNLA

Professor of Medicine
Section Head, General Cardiology,
Prevention and Imaging
University of Alabama at Birmingham
Birmingham, AL

Michael J. Bloch, MD, FNLA

Associate Professor
Department of Medicine
University of Nevada School of Medicine
Medical Director
Vascular Care
Renown Institute for Heart and Vascular Health
Reno, NV

Edward R. Chafizadeh, MD

Cardiologist
Cardio Texas
Austin, TX

Marina Cuchel, MD, PhD

Research Associate Professor
Perelman School of Medicine
University of Pennsylvania
Institute for Translational Medicine
Therapeutics Division of Translational Medicine
 and Human Genetics
Pennsylvania, PA

Samar R. El Khoudary, PhD, MPH

Associate Professor of Epidemiology
Epidemiology Data Center
University of Pittsburgh
Pittsburgh, PA

Robert P. Giugliano, MD, SM

Executive Committee, FOURIER Trial
Senior Investigator, TIMI Study Group
Physician, Cardiovascular Medicine
Brigham and Women's Hospital
Associate Professor
Harvard Medical School
Boston, MA

Ira J. Goldberg, MD, FNLA

Program Planner
Clarissa and Edgar Bronfman, Jr. Professor
Director, Division of Endocrinology, Diabetes and Metabolism
NYU Langone Medical Center
New York, NY

Tina M. Kaufman, PhD, PA-C

Assistant Professor of Medicine
Knight Cardiovascular Institute
Division of Cardiovascular Medicine
School of Medicine
Oregon Health and Science University
Portland, OR

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

Program Planner
Wellness Center Director
Clinical Assistant Professor
Idaho State University
Pocatello, ID

 

Marlys L. Koschinsky, PhD

Scientific & Executive Director
Robarts Research Institute
Schulich School of Medicine & Dentistry
Western University
London, ON, Canada

Penny Kris-Etherton, PhD, RD, CLS, FNLA

Distinguished Professor of Nutrition
College of Health and Human Development
Pennsylvania State University
University Park, PA

 

Ann M. Liebeskind, MD

Founder, Complex Lipids Clinic
Mobile Health Team
Neenah & Wauwautosa, WI 

Alberto J. Lorenzatti, MD

Co-Director, Medical Institute DAMIC
Rusculleda Foundation
Córdoba, Argentina

Santica Marcovina, PhD, DSc

Research Professor, Medicine
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, WA

Catherine J. McNeal, MD, PhD, FNLA

Associate Professor of Internal Medicine
Associate Professor of Pediatrics
Director, Nutrition and Weight Management Program
Baylor Scott & White Health
Temple, TX

Margo B. Minissian, PhD, ACNP, CLS

Nurse Scientist
Cardiology Nurse Practitioner
Cedars- Sinai Heart Institute
Barbra Streisand Women’s Heart Center
Los Angeles, CA

Patrick M. Moriarty, MD, FNLA

Professor of Medicine
Director of Clinical Pharmacology
University of Kansas Medical Center
Kansas City, KS

Pamela B. Morris, MD, FNLA

Program Planner
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Mt. Pleasant, SC

Kiran Musunuru, MD, PhD, MPH

Associate Professor
Cardiovascular Medicine and Genetics
University of Pennsylvania
Pennsylvania, PA

Roda Plakogiannis, PharmD, CLS, FNLA

Associate Professor of Pharmacy Practice
Long Island University, New York
New York, NY

Frank M. Sacks, MD, FNLA

Professor of Cardiovascular Disease Prevention
Department of Nutrition
and Genetics and Complex Disease
Harvard T. H. Chan School of Public Health
Professor of Medicine
Harvard Medical School
Senior Physician, Brigham & Women’s Hospital
Boston, MA

Julie St Pierre, MD, PhD

Associate Professor of Pediatrics
McGill University
Clinic 180
Chicoutimi, Quebec, Canada

Sandra J. Taler, MD

Professor of Medicine
Nephrology and Hypertension
Mayo Clinic
Rochester, MN

Vin Tangpricha, MD, PhD

Professor of Medicine
Division of Endocrinology, Metabolism and Lipids
Emory University School of Medicine
Atlanta, GA

David Wald, MD FRCP

Professor of Cardiology
Consultant Cardiologist
Wolfson Institute of Preventive Medicine
Queen Mary
University of London
London, England

Melissa F. Wellons, MD

Associate Professor of Medicine
Division of Diabetes, Endocrinology, and Metabolism
Department of Medicine
Vanderbilt University Medical Center
Nashville, TN

Anthony S. Wierzbicki, DM, DPhil, FRCPath

Department of Metabolic Medicine
Chemical Pathology
Guy’s and St. Thomas’ Hospital
London, United Kingdom

Kim A. Williams, Sr., MD

James B. Herrick Professor
Chief, Division of Cardiology
Rush University Medical Center
Chicago, IL

Lauren Williams, MCN, RD, LD

Clinical Dietitian II
Division of Pediatric Endocrinology
Cook Children’s Medical Center
Fort Worth, TX



REGISTRATION

Register for 2018 Scientific Sessions

Must be logged in to register at the NLA member price

SCIENTIFIC SESSIONS

April 26-29, 2018

  • NLA rate through 03/07/2018
    NLA Member
    $645.00
  • NLA rate after 03/07/2018
    NLA Member
    $695.00
  • Non-Member
    $1150.00
  • Trainee Member
    $75.00
  • Includes one admission badge to Exhibit Hall for all food functions.

ANCILLARY COURSES

April 25-26, 2018

  • MASTERS IN LIPIDOLOGY
  • NLA Member
    $750.00
  • Non-Member
    $1250.00
  • Trainee Member
    $395.00
  • Register Only for one of these
    Professional Development.

April 25-26, 2018

  • FOUNDATIONS OF LIPIDOLOGY
    (formerly Lipid Academy)
  • NLA Member
    $550.00
  • Non-Member
    $950.00
  • Trainee Member
    $0.00
  • Register Only for one of these
    Professional Development.

April 29, 2018

EVENT TICKETS

  • Foundation Event - Dinner Gala and Silent Auction
    Saturday, April 28 7:30-10:30pm
    The ticket price includes dinner, dancing, and a variety of unique items to bid on!

    $150.00



GUEST TICKETS






JOIN THE NLA AND REGISTER

  • Save on the Scientific Sessions Registration
    by becoming a Member of the NLA! Register now at the NLA Member Rate.

INTERESTED IN THE TRAINEE RATE?

Lipid Bucks: Lipid Bucks can be applied on the checkout page.

Registration: Online registration and payment must be received no later than April 26th, 2018. After this date, meeting materials and name badge cannot be guaranteed, but onsite registration will be available until April 29, 2018. By registering for this meeting, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By allowing an exhibitor to scan the conference badge, attendee understands, agrees and consents to the sharing of attendee’s contact information with the company that scanned the conference badge.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than March 26th, 2018. This includes social events and guest fees. There will be a $100 fee for all cancellations. There will be no refunds if cancelling within 30 days of the start of the meeting date.

Attendees who need special reasonable accommodations or who have special needs should contact the meeting organizers at 904-998-0854.